Mostrar el registro sencillo

dc.contributor.authorde Castro, María Josées_ES
dc.contributor.authorde Lamas, Carmelaes_ES
dc.contributor.authorSánchez Pintos, Paulaes_ES
dc.contributor.authorGonzález-Lamuño Leguina, Domingo es_ES
dc.contributor.authorCouce, María Luzes_ES
dc.contributor.otherUniversidad de Cantabriaes_ES
dc.date.accessioned2021-06-16T13:59:37Z
dc.date.available2021-06-16T13:59:37Z
dc.date.issued2020es_ES
dc.identifier.issn2072-6643es_ES
dc.identifier.urihttp://hdl.handle.net/10902/21887
dc.description.abstractPhenylketonuria (PKU) is the most common inborn error of amino acid metabolism. Although dietary and, in some cases, pharmacological treatment has been successful in preventing intellectual disability in PKU patients who are treated early, suboptimal outcomes have been reported, including bone mineral disease. In this systematic review, we summarize the available evidence on bone health in PKU patients, including data on bone mineral density (BMD) and bone turnover marker data. Data from cohort and cross-sectional studies of children and adults (up to 40 years of age) were obtained by searching the MEDLINE and SCOPUS databases following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. For each selected study, quality assessment was performed applying the Risk Of Bias In Non-randomized Studies of Interventions (ROBINS I) tool. We found that mean BMD was lower in PKU patients than in reference groups, but was within the normal range in most patients when expressed as Z-score values. Furthermore, data revealed a trend towards an imbalance between bone formation and bone resorption, favoring bone removal. Data on serum levels of minerals and hormones involved in bone metabolism were very heterogeneous, and the analyses were inconclusive. Clinical trials that include the analysis of fracture rates, especially in older patients, are needed to gather more evidence on the clinical implications of lower BMD in PKU patients.es_ES
dc.format.extent15 p.es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rights© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution(CC BY) license.*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.sourceNutrients . 2020 Jul 20;12(7):2154es_ES
dc.subject.otherBonees_ES
dc.subject.otherBone Mineral Densityes_ES
dc.subject.otherBone Turnover Markerses_ES
dc.subject.otherFractureses_ES
dc.subject.otherHyperphenylalaninemiaes_ES
dc.subject.otherOsteopeniaes_ES
dc.titleBone Status in Patients with Phenylketonuria: A Systematic Reviewes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherVersionhttps://doi.org/10.3390/nu12072154es_ES
dc.rights.accessRightsopenAccesses_ES
dc.identifier.DOI10.3390/nu12072154es_ES
dc.type.versionpublishedVersiones_ES


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution(CC BY) license.Excepto si se señala otra cosa, la licencia del ítem se describe como © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution(CC BY) license.